{{Rsnum
|rsid=2292566
|Gene=EPHX1
|Chromosome=1
|position=225831952
|Orientation=plus
|GMAF=0.1781
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Status=Merged
|Merged=1131873
|Gene_s=EPHX1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 1.8 | 19.5 | 78.8
| HCB | 5.2 | 43.3 | 51.5
| JPT | 9.8 | 37.5 | 52.7
| YRI | 1.4 | 30.1 | 68.5
| ASW | 0.0 | 17.5 | 82.5
| CHB | 5.2 | 43.3 | 51.5
| CHD | 9.2 | 40.4 | 50.5
| GIH | 8.9 | 37.6 | 53.5
| LWK | 0.9 | 22.0 | 77.1
| MEX | 1.7 | 20.7 | 77.6
| MKK | 1.3 | 10.3 | 88.5
| TSI | 3.0 | 31.7 | 65.3
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2292566
|Name_s=EPHX1, exon 3, c.357G>A, mRNA 632G>A, mRNA 398G>A, p.Lys119Lys
|Gene_s=EPHX1
|Feature=Exon/Syn
|Evidence=PubMed ID:19794411
|Annotation=Risk or phenotype-associated allele: A allele. Phenotype: Carriers of either one or two alleles of the A allele required 19% lower warfarin maintenance dose (2.6 &#177; 1.3 mg) compared to GG homozygotes (3.2 &#177; 1.6 mg) (p < 0.0001). The combined effect of variants in four genes, as well as age, explained 26.6% of the overall interindividual warfarin dose variability, with VKORC1 (rs9923231 A allele) accounting for 19.1%, CYP2C9 (rs1799853 T allele, or rs1057910 C allele) for 3.2%, EPHX1 (rs2292566 A allele) for 1.7%, CYP4F2 (rs2108622 C allele) gentoypes for 1.1%, and age for 1.5%. Study size: 283. Study population/ethnicity: Hospitalized Caucasian patients aged 75 years or older, recruited Sep 2002-Nov 2004 in Ivry, France, and Oct 2005-Mar 2008 from 14 French centers. Significance metric(s): p < 0.0001. Type of association: GN; PK.
|Drugs=warfarin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165111648
}}

{{PMID Auto
|PMID=19479063
|Title=Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression.
|OA=1
}}

{{PMID Auto
|PMID=21453055
|Title=Lack of association of EPHX1 genotypes and haplotypes with oral cancer in South Indians.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2292566
|overall_frequency_n=1529
|overall_frequency_d=10758
|overall_frequency=0.142127
|n_genomes=16
|n_genomes_annotated=0
|n_haplomes=17
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23061746
|Title=Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}